| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9012501 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(1 year, 4 months from now) | |
| US8383678 | ASTRAZENECA | Type a gelatin capsule containing PUFA in free acid form |
Feb, 2025
(1 year, 4 months from now) | |
| US9132112 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(1 year, 4 months from now) | |
| US7960370 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Dec, 2026
(3 years from now) | |
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
Epanova is owned by Astrazeneca.
Epanova contains Omega-3-Carboxylic Acids.
Epanova has a total of 7 drug patents out of which 0 drug patents have expired.
Epanova was authorised for market use on 05 May, 2014.
Epanova is available in capsule;oral dosage forms.
Epanova can be used as treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet, treatment of hypertriglyceridemia.
The generics of Epanova are possible to be released after 04 January, 2033.
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet
Dosage: CAPSULE;ORAL
EPANOVA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic